NSEInvestor Presentation4d ago · 6 Nov 2026, 11:50 am
Investor Presentation
Godrej Agrovet Limited · GODREJAGRO
✦ AI Summary▲ PositiveResults
Godrej Agrovet Limited has announced its Q2 FY27 financial results, showing a 17% revenue growth, flat EBITDA, and a 22% PAT growth. The company has delivered a double-digit revenue growth with sustained earnings resilience despite a challenging operating environment.
Analysis Scores
Earnings Impact8/10
Growth Catalyst6/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact8/10
Market Sentiment8/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Godrej Agrovet Limited has informed the Exchange about Investor Presentation
Attachments (1)
📄pdf
Download →
GODREJAGRO_06112026114951_BSENSEINVESTORSPRESENTATION06112026.pdf
View document text
Date: November 6, 2026
To, To,
BSE Limited National Stock Exchange of India Limited
P. J. Towers, Dalal Street, Exchange Plaza, Bandra - Kurla Complex,
Fort, Mumbai – 400001 Bandra (East), Mumbai - 400051
Ref.: BSE Scrip Code No. “540743” Ref.: “GODREJAGRO”
Sub: Presentation to Investors & Analysts
Dear Sir/Madam,
The Board of Directors of Godrej Agrovet Limited (“The Company”) at its Meeting held on Friday,
November 6, 2026, has approved the Standalone and Consolidated Unaudited Financial Results for the
Quarter and Half Year ended September 30, 2026.
We enclose herewith a copy of the presentation for the Investors and Analysts and the same is being
placed on the website of the Company i.e., www.godrejagrovet.com.
Kindly take the above on your record.
Thanking you,
Yours sincerely,
For Godrej Agrovet Limited
Vivek Raizada
Head- Legal & Company Secretary & Compliance Officer
(ACS 11787)
Encl.: As above
I NVEST OR PRESENT A T I ON
Q2 and H1 FY27 Performance Update
6 November, 2026
Disclaimer
This communication is provided for information purposes only and does not constitute (and should not be construed as) an offer,
invitation or solicitation to buy or sell any securities or other financial instruments, or any investment advice. Recipients should
make their own independent assessment and consult appropriate professional advisers. The information and opinions contained
herein are stated as of the date of this communication and are subject to change without notice; while reasonable care has been
taken in its preparation, the Company makes no representation or warranty, express or implied, as to the accuracy, completeness
or fairness of such information (including any third-party/industry data) and, to the fullest extent permitted by law, disclaims
any liability for any loss arising from the use of this communication or its contents. Certain statements herein may constitute
“forward-looking statements” under applicable laws and regulations, based on current expectations, assumptions and
information available to the Company, and involve risks and uncertainties that could cause actual results to differ materially,
including changes in economic and market conditions, competitive dynamics, laws, regulations, taxes and their interpretation,
foreign exchange and interest rate movements, demand and supply conditions, operational or supply-chain disruptions, labour
matters, litigation or regulatory proceedings, and the timing or impact of corporate actions. Forward-looking statements speak
only as of the date hereof and undue reliance should not be placed on them; except as required by law, the Company undertakes
no obligation to update or revise them. This communication should be read together with the Company’s disclosures and filings
made from time to time in accordance with applicable legal and regulatory requirements; where alternative performance
measures are included, they are presented for supplemental purposes, may not be comparable across companies, and should not
be viewed as a substitute for financial information prepared in accordance with applicable accounting standards.
2 I Godrej Agrovet
FINANCIAL
PERFORMANCE UPDATE
Operating environment remains highly volatile and challenging
El Niño impact Geopolitical volatility-led inflation
▪ El Niño intensified into a ‘super’ event in Q2; monsoon ended ▪ Unprecedented geopolitical disruptions kept
~13% short with wide spatial and temporal deviations, causing input costs high and volatile
drought, especially across southern and western India
▪ Commodity inflation felt across businesses,
▪ High carryover inventory and weak liquidation constrained particularly milk, packaging and feed inputs
channel demand in crop care; weaker kharif acreage and
crop damage in southern and western India added to the pressure ▪ Elevated CPO and PKO prices supported oil palm realizations
Reservoirs at 10-year low; impact on rabi crop to be monitored Inflationary trends likely to persist in the near term
4 I Godrej Agrovet
In this context, we delivered a double-digit revenue growth with
sustained earnings resilience through focused interventions
Q2 FY27 Highlights
1 7 % f l a t 5 % 2 2 %
Revenue growth EBITDA growth PBT growth PAT# growth
Driven by pricing ~120 bps margin impact ~50 bps margin Improved
and premiumization from input cost inflation contraction by ~10 bps
#PAT before non-controlling interest
5 I Godrej Agrovet
Q2 FY27 Segmental Summary
Revenue share, Q2 FY27
Animal Nutrition Oil Palm Crop Care
India
Revenue growth +14% Revenue growth +28% Revenue growth +42%
Cattle feed volume +8% FFB volume +14%
EBIT growth +32% EBIT growth +4% EBIT growth (23%)
Margin 6.7% ▲ 90 bps Margin 18.2% ▼ 420 bps Margin 12.6% ▼ 1,070 bps
ACI GAVL, Bangladesh
Volume +21%
PAT growth* +20%
Astec Lifesciences Creamline Dairy Godrej Foods
Revenue growth (3%) Revenue growth +6% Revenue growth +8%
Animal Nutrition 46%
VAP1 growth +12% B2C growth +50%
Oil Palm 27%
EBITDA lower vs. LY EBITDA (adj.) growth# (60%) EBITDA (adj.) growth# 12%
Creamline Dairy 14%
Margin (26%) ▼ 1,900 bps Margin (adj.)# 2.2% ▼ 350 bps Margin (adj.)# 5.8% ▲ 20 bps
Crop Care 7%
Godrej Foods 7%
Astec Lifesciences 2%
All changes vs. last year (LY). Brackets denote a decline. *In Indian Rupees.
Rounded; inter-segment sales
1Value Added Products
~3% of reported revenue
#EBITDA + working media; adjusting for investments made for brand building.
6 I Godrej Agrovet
Q2 FY27 P&L
Particulars (₹ cr) Q2 FY27 Q2 FY26 Change YoY
Revenue 2,995 2,564 17%
EBITDA 222 221 Flat
EBITDA margin % 7.4% 8.6% (120 bps)
Profit before Tax and
131 125 5%
share of profit of JV
PBT margin % 4.4% 4.9% (50 bps)
Profit after tax (PAT)# 103 84 22%
PAT margin % 3.4% 3.3% 10 bps
#PAT before non-controlling interest
7 I Godrej Agrovet
H1 FY27 P&L
Excluding non-recurring & exceptional items As reported
Change Change
Particulars (₹ cr) H1 FY27 H1 FY26 H1 FY27 H1 FY26
YoY YoY
Revenue 5,847 5,167 13% 5,847 5,167 13%
EBITDA 480 503 (4%) 476 503 (5%)
EBITDA margin % 8.2% 9.7% (150 bps) 8.1% 9.7% (160 bps)
Profit before Tax and
303 313 (3%) 299 313 (4%)
share of profit of JV
PBT margin % 5.2% 6.1% (90 bps) 5.1% 6.1% (100 bps)
Profit after tax (PAT)# 229 233 (2%) 231 233 (1%)
PAT margin % 3.9% 4.5% (60 bps) 4.0% 4.5% (50 bps)
#PAT before non-controlling interest
N.B.: please refer to slide 29 for non-recurring and exceptional items
8 I Godrej Agrovet
We continue to make progress against our long-term
strategic priorities across business segments
Business Strategic shift Key actions Progress
▪ Product ▪ Lifecycle segment focus; Samruddhi® expansion to Karnataka
Animal Nutrition mindset
premiumization ▪ Premium portfolio grew by ~20% vs. LY
Nutrition and premiumization
▪ Focus on profitable, scalable areas ▪ Exited shrimp business
▪ First phase of CPKO refinery
▪ Downstream specialty fats player
Differentiated, value- commissioned for specialty fats
Oil Palm
added products player
▪ Khammam mill (for CPO) commissioned in Jul, 26
▪ Upstream: geographical expansion
▪ Geographic expansion ahead of plan
▪ First maize herbicide rolled out; strong traction of Ashitaka®,
Product innovation, ▪ Crop diversification and with ~6X sales in H1 vs. LY
Crop Care
branding moat new crop segment ramp-up ▪ Strong scale-up of two more products (Takai®, Ghassnash®)
▪ New capabilities in brand building
Specialized, service-led ▪ Expand CDMO portfolio ▪ Four AI opportunities identified; two under development
Astec
CDMO player ▪ Build Dedicated BD engine ▪ Dedicated BD team being established
Creamline Value-added salience, ▪ VAP1 salience up from ~44% in H1 LY to ~49% in H1 FY27
▪ Increase in VAP salience
Dairy GTM revamp ▪ GTM revamp pilot commenced
▪ Strong B2C growth of ~42% in H1 vs. LY;
Protein-forward ▪ Focused, two-brand
Godrej Foods H1 salience up from ~26% to ~35% LY
foods portfolio B2C player
▪ Ramp-up of frozen chicken, momos and nuggets
▪ Upgradation, reformulation for
▪ Strong H1 volume growth across segments
Upgrade for
[Showing first 8,000 characters — download PDF for full document]